Abstracts Archive - Page 1706 of 2425 - ACR Meeting Abstracts

Abstract Number: 245 • 2015 ACR/ARHP Annual Meeting
Seasonal Variation in Acute Gouty Arthritis: Data from Nationwide Inpatient Sample
Paras Karmacharya¹, Ranjan Pathak², Madan Aryal², Smith Giri³ and Anthony Donato⁴, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, West Reading, PA, ³Internal medicine, University of Tennessee Health Science Center, Memphis, TN, ⁴Internal, Reading Health System, Salt Lake, UT
Background/Purpose: Studies describing seasonal variations in acute gouty arthritis note a seasonal trend, but disagree on timing, with most showing a peak in spring months…
Abstract Number: 246 • 2015 ACR/ARHP Annual Meeting
Adult Autoinflammatory Disease Frequency and Our Diagnostic Experience in an Adult Autoinflammatory Clinic
Qingping Yao¹, Felicitas Lacbawan² and Jianbo Li¹, ¹Cleveland Clinic, Cleveland, OH, ²Molecular Genetics Pathology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Autoinflammatory diseases (AIDs), aka, periodic fever syndromes include monogenic diseases, such as familial Mediterranean fever (FMF), cryopyrin-associated periodic disease (CAPS), tumor necrosis factor receptor-associated…
Abstract Number: 247 • 2015 ACR/ARHP Annual Meeting
Severe Inflammation Following Vaccination Against Streptococcus Pneumoniae in Patients with Cryopyrin-Associated Periodic Syndromes
Ulrich A. Walker^1,2, Philip N. Hawkins³, Rene Williams⁴, Hal M. Hoffman⁵ and Jasmin B. Kuemmerle-Deschner⁶, ¹Rheumatology, Unispital Basel, Basel, Switzerland, ²Rheumatology, University Hospital, Basel, Basel, Switzerland, ³University College London Medical School, London, United Kingdom, ⁴University College, London, England, ⁵University of California at San Diego, San Diego, CA, ⁶Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany
Background/Purpose: Pneumococcal vaccination is recommended for patients requiring treatment with immunosuppressive drugs. The aim of this report is to describe unusually severe adverse reactions to…
Abstract Number: 248 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with CAPS Aged <24 Months: Results from an Open-Label, Multicenter, Phase III Trial
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard R. Lauwerys⁴, Antonio Speziale⁵, K. Abrams⁶, Karolynn Leon⁷, Xiaoling Wei⁸ and Ronald Laxer⁹, ¹Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceutical Corporation, East Hanover, NJ, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma, Beijing, NU, China, ⁹University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Canakinumab (CAN) is indicated for the treatment of cryopyrin-associated periodic syndrome (CAPS) in patients aged ≥2 years.1,2 However, the efficacy of CAN has not…
Abstract Number: 250 • 2015 ACR/ARHP Annual Meeting
Postvaccination Antibody Titer Data in CAPS Patients Aged 28 Days to 4 Years Treated with Canakinumab: Results of an Open-Label Phase 3 Trial
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard R. Lauwerys⁴, Antonio Speziale⁵, Ken Abrams⁶, Karolynn Leon⁶, Xiaoling Wei⁷ and Ronald Laxer⁸, ¹Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma, Beijing, NU, China, ⁸University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Patients with autoinflammatory diseases treated with immunosuppressive agents reportedly experience an increased risk of serious infections.1 Therefore, these patients are likely candidates for vaccinations,…
Abstract Number: 251 • 2015 ACR/ARHP Annual Meeting
A New Genetic Mutation in TNF Receptor Associated Periodic Syndrome (TRAPS)
Mark Leith¹, Auleen Millar² and James Burns³, ¹Rheumatology, Antrim Area Hospital,, Antrim, Northern Ireland, ²Rhematology, Antrim area hospital, Antrim, Northern Ireland, ³Antrim area hospital, Antrim, Northern Ireland
Background/Purpose: ,We present the case of a family with a new diagnosis of TRAPs. The father, a 59 year old man with a history of…
Abstract Number: 252 • 2015 ACR/ARHP Annual Meeting
Pyrin (MEFV) Mutations in New York: Revisiting the Mount Sinai Experience with Periodic Fever and Serositis
Daniel Bunker and Mark Matza, Medicine, Mount Sinai Medical Center, New York, NY
Background/Purpose: In 1945, Dr. Sheppard Siegel, a Mount Sinai allergist, described 5 patients with “Benign Paroxysmal Peritonitis,” a disorder now recognized as Familial Mediterranean Fever…
Abstract Number: 253 • 2015 ACR/ARHP Annual Meeting
Multiple Serum Cytokine Profiling to Identify Specific Molecular Networks in Attacks of Familial Mediterranean Fever
Tomohiro Koga¹, Kiyoshi Migita², Shuntaro Sato³, Masataka Umeda⁴, Shoichi Fukui⁵, Ayako Nishino⁴, Shinya Kawashiri⁶, Naoki Iwamoto⁵, Kunihiro Ichinose⁵, Mami Tamai⁵, Hideki Nakamura⁵, Tomoki Origuchi⁷, Yukitaka Ueki⁸, Kazunaga Agematsu⁹, Katsumi Eguchi¹⁰ and Atsushi Kawakami⁴, ¹Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁸Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, ⁹Department of Infectious Immunology, Shinshu University, Graduate School of Medicine, Shinshu, Japan, ¹⁰Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan
Background/Purpose: Familial mediterranean fever (FMF) is caused by a number of mutations of the MEFV gene, coding for a protein named pyrin that acts as…
Abstract Number: 254 • 2015 ACR/ARHP Annual Meeting
The Interleukin-1 Inhibitor Canakinumab for Familial Mediterranean Fever: Long-Term Beneficial Effect in a Cohort of 13 Patients
KATERINA LASKARI¹, PANAGIOTA BOURA², GEORGE N DALEKOS³, ALEXANDROS GARYFALLOS⁴, DIMITRIOS KAROKIS⁵, DIMITRIOS PIKAZIS⁶, LOUKAS SETTAS⁷, GRIGORIS SKARANTAVOS⁸, ELENA TSITSAMI⁹ and PETROS P SFIKAKIS¹⁰, ¹Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Athens University Medical School, Athens, Greece, ²Clinical Immunology Unit, 2nd Dept. of Internal Medicine, Aristotle University Medical School, Thessaloniki, Greece, ³Thessaly University Medical School, Larissa, Greece, ⁴4th Department of Internal Medicine, Aristotle University Medical School, Thessaloniki, Greece, ⁵Private rheumatologist, Patras, Greece, ⁶Pathophysiology, Athens University Medical School, Athens, Greece, ⁷First Dept. of Internal Medicine, Rheumatology Section, Aristotle University Medical School, Thessaloniki, Greece, ⁸Bone Metabolic Unit, 1st Dept. of Orthopedics, Athens University Medical School, Athens, Greece, ⁹First Department of Pediatrics, Athens University Medical School, Athens, Greece, ¹⁰1st Dept. of Propaedeutic Internal Medicine, Athens University Medical School, Athens, Greece
Background/Purpose: Interleukin-1 (IL-1) is a major mediator of the inflammatory cascade in Familial Mediterranean Fever (FMF) and an established therapeutic target (1). To retrospectively assess…
Abstract Number: 255 • 2015 ACR/ARHP Annual Meeting
What Acute Phase Reactants Accurately Identify Patients Who Will Develop Amyloidosis in Familial Mediterranean Fever? a Systematic Review
Burak Erer¹, Erkan Demirkaya², Seza Ozen^3,4, Tilmann Kallinich⁵ and Loreto Carmona⁶, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Gulhane Military Medical Faculty, Ankara, Turkey, ³Pediatric Nephrology and Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ⁴Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ⁵Charite, University Medicine Berlin, Berlin, Germany, ⁶Instituto de Salud Musculoesqueletica, Madrid, Spain
Background/Purpose: Familial Mediterranean Fever (FMF) is a prototype of autoinflammatory diseases. Inflammation is expressed by attacks of fever and serositis and elevation of acute phase…
Abstract Number: 256 • 2015 ACR/ARHP Annual Meeting
The Predominant Attack Type and Associated Clinical-Laboratory Conditions in Patients with Familial Mediterranean Fever
Mustafa Cakar¹, Muharrem Akhan², Muhammet Cinar¹ and Sedat Yılmaz¹, ¹Rheumatology, Gulhane Medical Faculty, Ankara, Turkey, ²Internal Medicine, Gulhane Medical Faculty, Ankara, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever and serositis. Abdominal pain is the most frequent symptom of…
Abstract Number: 257 • 2015 ACR/ARHP Annual Meeting
Investigation of the Arterial Stiffness and Associated Factors in Patients with Familial Mediterranean Fever
Mustafa Cakar¹, Muharrem Akhan², Tolga Doğan², Gurhan Taskin³, Kadir Ozturk⁴, Muhammet Cinar¹, Erol Arslan² and Sedat Yılmaz¹, ¹Rheumatology, Gulhane Medical Faculty, Ankara, Turkey, ²Internal Medicine, Gulhane Medical Faculty, Ankara, Turkey, ³Internal Medicine Intensive Care, Gulhane Medical Faculty, Ankara, Turkey, ⁴Gastroenterology, Gulhane Medical Faculty, Ankara, Turkey
Background/Purpose: Arterial stiffness represents the viscoelastic properties of the vessel wall. It occurs as a result of known atherosclerotic risk factors such as hypertension, diabetes…
Abstract Number: 258 • 2015 ACR/ARHP Annual Meeting
Quality of Life Changes with Canakinumab Therapy in Adults with Colchicine Resistant FMF
Ahmet Gul¹, Huri Ozdogan², Ozgur Kasapcopur³, Burak Erer⁴, Serdal Ugurlu⁵, S. Sevgi⁶ and Soner Turgay⁷, ¹Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Professor of Pediatric Rheumatology, Istanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Rheumatology, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁶Novartis Pharma, Istanbul, Turkey, ⁷Medical, Novartis Pharma, İstanbul, Turkey
Background/Purpose: Introduction:Familial Mediterranean Fever (FMF), the most common form of the hereditary autoinflammatory disorders, is characterized by recurrent attacks of fever along with serosal or…
Abstract Number: 259 • 2015 ACR/ARHP Annual Meeting
How Safe IT Is to TREAT Pregnant FMF Patients with Anakinra ?
Huri Ozdogan¹, Serdal Ugurlu² and Bilgesu Ergezen¹, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: To assess the safety and efficacy of anakinra in pregnant FMF patients. Methods: Six FMF patients, treated with anakinra during pregnancy were monitored for…
Abstract Number: 260 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Is Effective in the Treatment of AA Amyloidosis Secondary to Familial Mediterranean Fever
Huri Ozdogan¹, Serdal Ugurlu², Aysa Hacioglu², Yasaman Adibnia² and Vedat Hamuryudan², ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Rheumatology, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: AA amyloidosis is the long-term complication of various chronic inflammatory diseases avoidable by the treatment of the underlying disease but with no established treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].